Show simple item record

dc.contributor.authorPopat, S
dc.contributor.authorGrohé, C
dc.contributor.authorCorral, J
dc.contributor.authorReck, M
dc.contributor.authorNovello, S
dc.contributor.authorGottfried, M
dc.contributor.authorRadonjic, D
dc.contributor.authorKaiser, R
dc.coverage.spatialIreland
dc.date.accessioned2022-09-16T09:52:16Z
dc.date.available2022-09-16T09:52:16Z
dc.date.issued2020-06-01
dc.identifierS0169-5002(20)30378-0
dc.identifier.citationLung Cancer, 2020, 144 pp. 76 - 84en_US
dc.identifier.issn0169-5002
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5495
dc.identifier.eissn1872-8332
dc.identifier.eissn1872-8332
dc.identifier.doi10.1016/j.lungcan.2020.04.009
dc.identifier.doi10.1016/j.lungcan.2020.04.009
dc.description.abstractThe introduction of licensed front-line immunotherapies has heralded a new era for the treatment of non-oncogene-addicted, advanced non-small cell lung cancer (NSCLC). Yet as with all evolutions in clinical management, changes in practice can outpace the availability of the clinical evidence needed to inform subsequent therapeutic decision making. At the time of writing, there is limited available evidence on the optimum therapeutic options after progression on immunotherapy. Further research is needed to define mechanisms of immunotherapy resistance in patients with advanced NSCLC, and to understand the implications for subsequent treatment response. Pending the availability of robust clinical data and proven therapeutic options to underpin an optimized therapeutic pathway after progression on immunotherapy, attention must turn to the potential utility of currently licensed agents and any available supporting clinical data in this setting. Within this context we review the mechanistic arguments and supporting evidence for the use of anti-angiogenic agents as a means of targeting immunosuppression within the tumor microenvironment. We consider whether VEGF inhibition may help to normalize the tumor vasculature and to address immunosuppression - reinstating, and potentially enhancing, the effect of subsequent therapies. We also highlight evidence needs and signpost ongoing trials that should enable current clinical opinion in this area to be replaced by robust, evidence-based guidance.
dc.formatPrint-Electronic
dc.format.extent76 - 84
dc.languageeng
dc.language.isoengen_US
dc.publisherELSEVIER IRELAND LTDen_US
dc.relation.ispartofLung Cancer
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectAnti-angiogenic drug
dc.subjectImmunotherapy resistance
dc.subjectNintedanib
dc.subjectNon-oncogene-addicted non-small cell lung cancer (NSCLC)
dc.subjectTumor microenvironment (TME)
dc.subjectVascular endothelial growth factor (VEGF)
dc.subjectAngiogenesis Inhibitors
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectHumans
dc.subjectImmune Checkpoint Inhibitors
dc.subjectImmunotherapy
dc.subjectLung Neoplasms
dc.subjectTumor Microenvironment
dc.titleAnti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?en_US
dc.typeJournal Article
dcterms.dateAccepted2020-04-09
dc.date.updated2022-09-16T09:51:52Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1016/j.lungcan.2020.04.009en_US
rioxxterms.licenseref.startdate2020-06-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/32387684
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1016/j.lungcan.2020.04.009
pubs.volume144
dc.contributor.icrauthorPopat, Sanjay
icr.provenanceDeposited by Mr Arek Surman on 2022-09-16. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S0169500220303780-main.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/